Table 2. Summarized results for single and multiple doses of benzathine penicillin G for early syphilis in HIV co-infected persons from observational studies.
| Author | BP-G doses1 |
Serological response2 at 12 months | HIV association with serological response | ||
|---|---|---|---|---|---|
| Response | p value | Response | p value | ||
| Cousins (39) 2012 | 1 dose | 78.9% (95% CI 68.0-89.8) | p > 0.05 | N/A | |
| 3 doses | 64.1% (95% CI 45.0-73.2) | N/A | |||
| Knaute (40) 2012 | 1 dose | 100% | HIV-negative (reference) | ||
| 3 doses | 100% | CD4 ≥500 HR 1.27 (95% CI 0.79-2.04) CD4 < 500 HR 0.83 (95% CI 0.60-1.14) |
p = 0.332 p = 0.241 |
||
| Tittes (41) 2013 | 1 dose | 88% | No correlation between viral suppression and outcome – data not shown | p = 0.18 | |
| 3 doses | 97% | ||||
| Yang (45) 2014 | 1 dose | 66.2% (95% CI 59.6–72.4) | p = 0.24 | CD4 ≤ 200 (reference) | |
| 3 doses | 71.8% (95% CI 64.7–78.2) | 200 < CD4 ≤ 350 ORADJ 1.05 (95% CI 0.54-2.07) CD4 > 350 ORADJ 1.51 (95% CI 0.69-3.51) |
p = 0.88 p = 0.30 |
||
| Ganesan (38) 2015 | 1 dose | 92% | CD4 (per 100-cell increase) HR 1.07 (95% CI 1.01-1.12) | p = 0.02 | |
| ≥2 doses | 92% | ||||
Abbreviations: BP-G, benzathine penicillin G; CD4, cluster of differentiation; CI, confidence interval; HIV, human immunodeficiency virus; HR; higher rate; ORADJ, odds ration adjusted. 1 Dose = 2.4 million units BP-G IM in a single dose 2 Proportion of subjects who exhibited response to therapy defined as a ≥4-fold decline in nontreponemal titre